AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the ...

ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a ...

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...

Experience healthcare exec Tameeka Smith appointed CEO of CQ fluency, as founder Elisabete Miranda transitions to Board ...

The 2025 report highlights China’s rapid biopharma rise, along with steady global growth and booming biologics   LONDON – 24 June 2025 – Evaluate, the leading provider of market insights for the ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

The trial judged the tolerability, safety and efficacy of atogepant, at 60 milligrams once daily, compared to the ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

The White House is reportedly considering measures to limit pharma companies’ ability to conduct so-called direct-to-consumer advertising. Senators introduced a bill this month that would ban the ...